Royal Bank of Canada Has $10.08 Million Stock Position in iShares U.S. Pharmaceuticals ETF $IHE

Royal Bank of Canada reduced its position in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) by 25.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 116,293 shares of the company’s stock after selling 40,680 shares during the period. Royal Bank of Canada owned about 1.08% of iShares U.S. Pharmaceuticals ETF worth $10,080,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Goldman Sachs Group Inc. boosted its stake in iShares U.S. Pharmaceuticals ETF by 4.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 104,815 shares of the company’s stock worth $7,396,000 after purchasing an additional 4,815 shares during the period. JPMorgan Chase & Co. raised its stake in iShares U.S. Pharmaceuticals ETF by 781.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 110,936 shares of the company’s stock valued at $7,271,000 after purchasing an additional 98,352 shares during the period. Raymond James Financial Inc. lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 3.2% in the second quarter. Raymond James Financial Inc. now owns 63,564 shares of the company’s stock valued at $4,166,000 after purchasing an additional 1,955 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of iShares U.S. Pharmaceuticals ETF by 491.9% in the second quarter. Ameriprise Financial Inc. now owns 23,658 shares of the company’s stock worth $1,550,000 after buying an additional 19,661 shares during the period. Finally, BNP Paribas Financial Markets acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF in the second quarter worth $13,108,000.

iShares U.S. Pharmaceuticals ETF Stock Performance

Shares of IHE stock opened at $102.47 on Monday. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 17.75 and a beta of 0.48. iShares U.S. Pharmaceuticals ETF has a 1-year low of $65.60 and a 1-year high of $105.02. The stock’s fifty day simple moving average is $98.00 and its 200-day simple moving average is $91.60.

iShares U.S. Pharmaceuticals ETF Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.